Severe Raynaud's phenomenon is often the most troublesome manifestation of SS and is difficult to treat successfully. Increased platelet activation may be a factor in its causation. ' The use of prostanoids, prostaglandin E,2 and prostacyclin,3 which are potent vasodilators and inhibit platelet aggregation, has been shown to alleviate symptoms in many patients. Rapid metabolism in vivo, however, may limit their therapeutic potential. Iloprost is a chemically stable carbacyclin derivative of prostacyclin with a half life exceeding that of prostacyclin by a factor of 10.) It has been shown to be more potent than prostacyclin as an antiplatelet agent but induces less vasodilatation.6 It inhibits platelet aggregation in patients with progressive systemic sclerosis (PSS) when given by a five hour intravenous infusion. 7 A pilot study using Iloprost infusion in 12 patients with secondary Raynaud's phenomenon showed improvement in symptoms and an increase in digital blood flow for up to five weeks after therapy (unpublished data). We chose to assess the effectiveness of Iloprost compared with placebo in a larger number of patients with severe Raynaud's phenomenon secondary to PSS in a randomised Accepted for publication 22 Twenty out of 25 patients who completed the study maintained their diaries regularly and accurately enough for them to be analysed. There were no significant differences in the baseline diary card data between the two treatment groups ( Table 2) . tValues are means (I-P) with absolute baseline values given in parentheses. Table 2 shows the percentage change from baseline for number, duration, severity, and proportion of painful attacks, comparing placebo and Iloprost for the two groups receiving either Iloprost or placebo first. A negative sign indicates greater benefit from Iloprost than from placebo. Probabilities are given for a treatment period interaction (e.g., hangover effect of the drug beyond six weeks of the single drug effect), a treatment effect (i.e., one treatment more effective than another), and period effects (i.e., the first or second period more effective than the other, independent of the drug treatment). Week 1 after treatment was excluded from the analysis as there was a significant period effect.
Iloprost was significantly more effective than placebo in reducing the number of attacks (p=0035) and the severity of attacks (p=0-013) of Raynaud's phenomenon for weeks 2-6 after treatment, and this trend was shown throughout the study period. The duration of attacks in general was reduced more by Iloprost than placebo, though this only reached statistical significance at week 5 after treatment. No difference between Iloprost and placebo was shown in the proportion of painful attacks.
Over the six week period (Fig. 1) patients receiving Iloprost showed an average reduction in the number of attacks of 30% compared with a placebo response of 2%. Duration of attacks was reduced by an average of 9% by Iloprost, whereas with placebo the duration of attacks was increased by 26% over the six week period. Iloprost reduced the severity of attacks by 20% and during the placebo period severity was reduced by 1% (Fig. 2) .
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[5~~3placebo 10 O_ Four patients withdrew from the study. Three of those had received placebo infusions only before withdrawing, two withdrawing because of concurrent illness and one because of his inability to attend owing to adverse weather conditions. One patient withdrew from the group that received Iloprost first. After the first treatment, during which this patient developed diarrhoea, her symptomatology was improved and she felt a second treatment was not necessary.
Discussion
We have shown that Iloprost, given by three sixhour infusions on successive days to patients with PSS significantly reduces the frequency and severity of attacks of Raynaud's phenomenon compared with placebo. The average reduction in frequency of Raynaud's attacks for the six weeks after Iloprost infusions was 30% and the reduction in severity of attacks 20%. Subjective patient response to treatment in terms of benefit or otherwise similarly showed Iloprost to be more effective than placebo. Of nine patients who reported only one of the treatments effective, eight of these were in favour of Iloprost.
These results are in accord with results from reported studies using native prostacyclin 3 4 and with results from a previous double blind study using Iloprost.8 In the latter study both patients' symptoms were improved and digital blood flows measured using laser-Doppler techniques were shown to be improved for up to five weeks after Iloprost treatment. In a more recent open study digital peripheral vascular resistance measured using plethysmographic methods was found to be decreased in patients with Raynaud's phenomenon for 6-10 weeks after Iloprost treatment. 12 In the present study no changes in digital thermal gradients before and after cold stress were detected after Iloprost or placebo. The thermal gradient is a good objective measure of reduced digital blood flow in patients with Raynaud's phenomenon. It may not reflect the subjective changes produced by this treatment. The measurement of rewarming times by thermography has been suggested as an alternative method for distinguishing changes in vasospasticity of the digital vessels.9
There was no difference between Iloprost and placebo in healing ischaemic lesions, though the crossover design and short follow up period of the present study make interpretation difficult. There were a few notable exceptions, with the two youngest patients also with the shortest duration of disease showing definite improvement in healing of active lesions with Iloprost but not with placebo, suggesting that Iloprost may be more effective for this category of patient.
Side effects during Iloprost infusion were common. Flushing and headache at least could be attributed to the vasodilative action of Iloprost. There were no hypotensive events, no longlasting adverse effects, and lowering of the infusion rate and use of an antiemetic prophylactically allowed continuation of treatment in all cases.
In conclusion, Iloprost is effective in reducing the number and severity of Raynaud's attacks in PSS for up to six weeks after infusion and may improve active skin lesions in some cases. Its routine use is limited by the common occurrence of unpleasant side effects and the inconvenience of intravenous administration. Alternative treatment regimens using Iloprost may prove to be as effective and more acceptable. 
